EMBC
Embecta Corp. · Healthcare · Medical - Instruments & Supplies
Momentum inputs (comparable managers):
holder breadth -9.1% ·
share flow -6.7% ·
net new positions -10.0%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 82 | -4 | 27.59M | $90.42M | +11 | −16 |
| Q1 2026 | 90 | -9 | 35.88M | $317.56M | +2 | −11 |
| Q4 2025 | 98 | +3 | 38.68M | $459.60M | +3 | — |
| Q3 2025 | 18 | +1 | 23.51M | $331.78M | +3 | −2 |
| Q2 2025 | 14 | +1 | 21.26M | $206.03M | +3 | −2 |
| Q1 2025 | 10 | -1 | 6.04M | $76.89M | — | −1 |
| Q4 2024 | 11 | -1 | 6.48M | $133.73M | — | −1 |
| Q3 2024 | 11 | +1 | 5.91M | $83.38M | +2 | −1 |
| Q2 2024 | 10 | — | 7.60M | $94.96M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 2.38M | +0.7% | $30.40M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.47M | +6.0% | $18.71M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 3 | Millennium Management ✦ | 886.95K | -21.4% | $11.31M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 831.57K | -6.5% | $10.60M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 5 | AQR Capital Management ✦ | 225.64K | +3.7% | $2.74M | 0.0% | ▲ Add | 4 | SEC ↗ ×5 |
| 6 | Citadel Advisors ✦ | 106.63K | +9.5% | $1.36M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | T. Rowe Price ✦ | 61.82K | +3.8% | $789,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 46.45K | -32.5% | $592,212 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Marshall Wace ✦ | 20.04K | -76.1% | $255,498 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Gotham Asset Management ✦ | 10.87K | +5.3% | $138,542 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Arrowstreet Capital | $3.49M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 335 holders, 60.19M shares, $506.91M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer · SVP and CFO · 20.00K sh @ 4.67 · $93,360
Director · 45.00K sh @ 4.97 · $223,848
Officer · Pres, Pharm Svc&Prod… · 20.00K sh @ 4.99 · $99,800
Officer, Director · President and CEO · 30.00K sh @ 4.70 · $140,937
Open-market sales (S)
Director · 6.29K sh · $36,971
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology